{"entity":{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","aka":[],"tldr":"Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade.","summary":"Alberto Bardelli led the 2012 Nature study showing that KRAS mutations emerge in the blood of colorectal cancer patients months before radiological progression on cetuximab or panitumumab, one of the first demonstrations of liquid biopsy for tracking resistance, and later showed these clones decay when anti-EGFR therapy is stopped, the basis for rechallenge strategies. His laboratory also showed that mismatch repair inactivation increases immunotherapy sensitivity.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Alberto_Bardelli","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardelli%20A%5BAuthor%5D%20colorectal%20ctDNA"}],"tags":["ctdna","colorectal","resistance"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["liquid-biopsy"],"targets":["egfr","kras"],"drugs":[],"companies":[],"institutions":["candiolo","airc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Scientific Director, IFOM ETS - The AIRC Institute of Molecular Oncology; Professor, University of Turin","institutionId":"candiolo","specialisms":["Colorectal cancer genomics","Liquid biopsy","Acquired resistance","Tumour evolution"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bardelli%20A%5BAuthor%5D%20colorectal%20ctDNA"}],"papers":[{"title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","journal":"Nature","year":2012,"doi":"10.1038/nature11156"},{"title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","journal":"Nature","year":2017,"doi":"10.1038/nature24673"}],"orcid":"0000-0003-1647-5070"},"route":"/people/alberto-bardelli/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"institution":[{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/"},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/"}],"paper":[{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/"},{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}]}}